Jose Gomez-Marquez

10.3K posts

Jose Gomez-Marquez banner
Jose Gomez-Marquez

Jose Gomez-Marquez

@jfgm

Building something new. Founded IRL DIY Medtech @littledevices Make 🛠so MD+RNs invent @makerhealthco Rocket launching. Robotbio TEDFellow 🇪🇸🇭🇳 MIT➡️Emory

Jose.gomez.marquez on Threads Beigetreten Nisan 2009
1K Folgt3.1K Follower
Angehefteter Tweet
Jose Gomez-Marquez
Jose Gomez-Marquez@jfgm·
Whirlwind jet into Iowa for a Unity Point St Luke’s hospital Maker Faire. Each year, it’s a unique vibe. 2024’s reflected a confident clinical community where health making is part of the fabric of innovative caring for patients with @makerhealthco @RHedgesRN @annakyoung
Jose Gomez-Marquez tweet mediaJose Gomez-Marquez tweet mediaJose Gomez-Marquez tweet mediaJose Gomez-Marquez tweet media
English
1
0
6
420
Jose Gomez-Marquez retweetet
Tim Hirschel-Burns
Tim Hirschel-Burns@TimH_B·
However dumb you think the process for destroying USAID was, it was dumber. This is from Nicholas Enrich's new book Into the Wood Chipper, describing a meeting with Trump-appointed USAID leadership *after* they had largely gutted the agency
Tim Hirschel-Burns tweet mediaTim Hirschel-Burns tweet mediaTim Hirschel-Burns tweet mediaTim Hirschel-Burns tweet media
English
161
3.3K
13.1K
563.9K
Jose Gomez-Marquez retweetet
Rimsha Bhardwaj
Rimsha Bhardwaj@heyrimsha·
🚨BREAKING: The "Cursor for scientific research" just dropped and it runs entirely inside Claude Code. It's called claude-scientific-skills and it gives Claude 140 ready-to-use scientific skills from a single plugin install. No API doc hunting. No library configuration. No duct-taped research pipelines. It's powered by 28+ live scientific databases wired directly into Claude. → Describe your research goal in plain English → Claude finds the right skill automatically → Full pipeline runs: data retrieval → analysis → publication-ready output → Works across biology, chemistry, medicine, ML, and clinical research All running inside Claude Code. Zero manual setup. But it's not just a prompt library. It's a full AI research lab: → Drug discovery: ChEMBL → RDKit → DiffDock → lead optimization in one prompt → Genomics: 10X data → Scanpy → GRN inference → pathway enrichment → Clinical: VCF → ClinVar → pharmacogenomics → patient report → Multi-omics: RNA-seq + proteomics + metabolomics integrated automatically 7.8k stars. 924 forks. MIT Licensed. MacOS, Windows, Linux works everywhere Claude Code runs. This is the moment AI stops being a chat tool and becomes an actual research partner. Link in the first comment 👇
Rimsha Bhardwaj tweet media
English
26
137
873
78.8K
Jose Gomez-Marquez retweetet
David Lang
David Lang@davidtlang·
Dempsey hit a chord—a topic that’s been lighting up my private conversations lately: *Post-Founder Archetypes* The moment feels similar to 2008, when finance careers went from highly coveted to passé. The social hierarchy seems to run on these ~20-year cycles. The question now: what comes next? I'll go a step further than Dempsey. I'm predicting the rise of the *bricoleur*, in the Lévi-Strauss sense of the term: someone who can make and *remake* things with the tools at hand. There's never been a better time to be a maker of things and stories, including your own personal myths. If you're unbound by the dogma of product/market fit, the world opens widely, ready to be remade by a small group of friends. I've also noticed the most interesting people I know are having a *terrible* time answering the "what do you do?" question. They can tell you about a project they're working on, but they'll shirk any qualifying identity description, including and especially "founder". My favorite analogy comes from biology: monopodial vs sympodial growth in trees. Monopodials (like redwoods) have one big trunk and aim for continuous vertical growth. Sympodials (like oaks) grow via multiple branches. The metabolic strategies are very different. Monopodials put all their energy into growing tall quickly, whereas the sympodial plants hedge with multiple different leading edges, which is more resilient. The next high-status career will be sympodial. Or what @zebriez called Flounder Mode—moving from project to project with people you like, and not letting your identity get too tangled up with any one of them.
David Lang tweet media
Michael Dempsey@mhdempsey

(New Essay) VC-Backed Startups are Low Status The traditional VC-backed startup path is becoming low status in the same way investment banking did. An aesthetic collapse across institutions, ideas, and founders paired with the world's tiring of tech has recently accelerated this shift. Some thoughts on the cascade, the generational divide, Anthropic vs. OpenAI, what comes next, and more.

English
1
4
15
3.8K
Sri Kosuri
Sri Kosuri@srikosuri·
After 9 months, 5 rounds of chemo, and getting to ring the cancer-free bell, we got to come home today from @StJude. Definitely counting our blessings over the holidays and so happy to be home.
Sri Kosuri tweet mediaSri Kosuri tweet media
English
222
103
4.8K
160.1K
Jose Gomez-Marquez retweetet
Rep. Jake Auchincloss 🟧
Rep. Jake Auchincloss 🟧@RepAuchincloss·
They do not research medicines. They do not manufacture medicines. They do not dispense medicines. So why are insurance companies making billions off medicines?
English
26
45
164
11.8K
Jose Gomez-Marquez
Jose Gomez-Marquez@jfgm·
@chr1sa @ashleevance Also, remember that overhead generally doesn't buy you deliverables. When I was at MIT our contracts couldn't have a deliverable beyond a report of findings because we weren't a contractor or a consulting company. Hard sell for most companies.
English
0
0
2
251
Chris Anderson
Chris Anderson@chr1sa·
@ashleevance The universities created this problem with the administrative bloat that led to 50-60% of every federal research dollar going to "overhead". The EU is 20%. Private research funding is usually capped at 10-20%.
English
15
9
315
23.1K
Ashlee Vance
Ashlee Vance@ashleevance·
Just hung out at Stanford Friday evening and with a friend from CalTech today. The depression levels are high. Labs disappearing from lack of funding. Nobel Prize winners not safe. Are the schools really not going to backstop this with their billions?
English
53
53
1.3K
256K
Jose Gomez-Marquez
Jose Gomez-Marquez@jfgm·
@emollick I'm curious, why only one author? Is this is an Econ thing? Presumably he had PhD supervisors?
English
0
0
0
206
Ethan Mollick
Ethan Mollick@emollick·
Paper shows that AI (in this case a diffusion model) accelerates innovation. Among key findings: 1) GenAI increases novel discoveries: a 39% increase in patent filings! 2) It boosts the best performers by acting as a co-intelligence 3) It takes away some of the fun parts of work
Ethan Mollick tweet mediaEthan Mollick tweet mediaEthan Mollick tweet media
English
23
115
613
127.5K
Ethan Perlstein 1-to-N
Ethan Perlstein 1-to-N@eperlste·
The job in Silicon Valley most under threat from AI is that of cofounder. Agentic AI will stretch solo founders to new limits. Reasoners will serve as tireless sparring partners who can speak to every aspect of the business. Hub-and-spoke operations running through a solo founder are anti-dilutive to stakeholders, hyper capital efficient, and execute at faster speed. A good chunk of startups fail because of cofounder issues. With AI as cofounder, every founder can now go solo. The startup ecosystem will gradually become a global decentralized network of AI-powered solo founders interacting onchain with each other, investors and customers.
English
2
1
16
2.1K
Jose Gomez-Marquez retweetet
Georgia Tech College of Engineering
A new lab model from @WilburLam & team can sustain blood clots for a long time, allowing detailed study of how they form and resolve. It opens new paths for treatment, with big implications for stroke, heart attack, sickle cell & more. Now out in @Nature. bit.ly/4i8M7L3
Georgia Tech College of Engineering tweet media
English
1
4
9
680
Jose Gomez-Marquez retweetet
Antonio Ciaccia
Antonio Ciaccia@A_Ciaccia·
"While dealing with the challenges of cancer, a 30-day supply of his medication costs $6,067.69 through his employer’s PBM. Of that, the employee paid $1,213.54 out-of-pocket, while his employer covered $4,854.15. With RxSaveCard, the total cost of the drug is just $13.18 through @costplusdrugs. His employer pays $13.18 and the employee gets his cancer medication for free." medcitynews.com/2025/02/rxsave…
English
5
21
67
13.3K
Leyla
Leyla@LeylaKuni·
Why are more residential homes not built with concrete? Is it cost? Seismic code? Smth else?
English
590
148
4.7K
2M
Jose Gomez-Marquez
Jose Gomez-Marquez@jfgm·
@AustinTunnell @LeylaKuni I grew up in Honduras and my stone + brick + concrete house was likely cheaper than the equivalent lumber American made one. And a few hurricanes later, it’s still standing just fine. I’ve never understood why we don’t do stone / brick/ concrete here.
English
0
0
1
66
Austin Tunnell
Austin Tunnell@AustinTunnell·
Because lumber mills and mass-produced nails were invented as we were expanding rapidly, and so all industry, regulations and trades ended up focusing on wood frame construction. Particularly at the beginning of the 20th century. I’m an advocate for conventional wood frame for fast-and-cheap housing, which we need as places evolve, etc. But it’s absolutely ridiculous we have not shifted to a masonry-based construction system (including concrete) for maturing places and higher end construction. We essentially build really cheap houses but stuff more and more expensive finishes inside. We are some of the only people in the world who do this. But the houses look good with the final paint and lipstick! Masonry may be vulnerable to seismic (though can be solved for), it’s WAY better in terms of fire, termites, rot, mold, high wind, etc.
English
57
57
1.1K
140K